Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00230165 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
NotablePrimary and study completion dates: Jun 2016 to Jun 2019v18
MinorPrimary and study completion dates: Dec 2015 to Jun 2016v17
MinorCollaborators expanded, about 7 wordsv16
NotablePrimary and study completion dates: Dec 2013 to Dec 2015v15
Minor3 versionsRe-verified since Aug 8, 2012, no change to tracked fieldsv12-v14
NotablePrimary and study completion dates: Dec 2012 to Dec 2013v11
NotablePrimary and study completion dates: Dec 2009 to Dec 2012v10
Minor3 versionsRe-verified since Nov 11, 2009, no change to tracked fieldsv7-v9
MinorEnrollment target: 60
Primary and study completion dates: Dec 2009
Eligibility criteria expanded, about 260 words
Study title shortened, about 2 words
v6
MinorRe-verified, no change to tracked fieldsv5
MinorStudy description expanded, about 52 words
Eligibility criteria shortened, about 1 word
v4
Minor2 versionsRe-verified since Apr 25, 2006, no change to tracked fieldsv2-v3
MinorStudy First Submitted
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Blood contains red blood cells, white blood cells, and platelets, as well as a fluid portion termed plasma. We primarily study blood platelets, but sometimes we also analyze the blood of patients with red blood cell disorders (such as sickle cell disease), white blood cell disorders, and disorders of the blood clotting factors found in plasma.
Blood platelets are small cell fragments that help people stop bleeding after blood vessels are damaged. Some individuals have abnormalities in their blood platelets that result in them not functioning properly. One such disorder is Glanzmann thrombasthenia. Most such patients have a bleeding disorder characterized by nosebleeds, gum bleeding, easy bruising (black and blue marks), heavy menstrual periods in women, and excessive bleeding after surgery or trauma. Our laboratory performs advanced tests of platelet function and platelet biochemistry. If we find evidence that a genetic disorder may be responsible, we analyze the genetic material (DNA and RNA) from the volunteer, and when possible, close family members to identify the precise defect.